Malaria Studies in Cambodia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1978 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-03-24

Study Completion Date

2013-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study, conducted by the National Center for Parasitology, Entomology and Malaria Control of Cambodia s Ministry of Health and the National Institute of Allergy and Infectious Diseases, will explore whether the following factors confer protection against malaria and associated anemia: certain blood groups, the hemoglobin E variant, G6PD-deficiency and alpha-thalassemia. Malaria is caused by parasites (P. falciparum and P. vivax) that are transmitted to humans through mosquito bites. This protocol includes two studies, a cohort study and a P. vivax collection study.

Individuals are eligible for enrollment in the studies as follows:

Cohort study:

Residents of all ages of Kandal, Ekapheap and Sangkumthmey villages (Thmar Da commune) who plan to remain in Thmar Da commune for the next 5 years.

P. vivax collection study:

2 years of age and older

Participating in NIAID protocol 05-I- N210 ( Severe Malaria and Anti-malarial Drug Resistance in Cambodia ) and diagnosed with P. vivax malaria

Participants undergo the following procedures:

Cohort study:

Baseline evaluation, including the following:

* Collection of demographic information
* Malaria history, temperature measurement and review of current symptoms, if any
* Blood draw of 300 microliters
* Additional blood draw of 10 milliliters in selected adults 18 years of age and older

Treatment with artesunate-piperaquine at a commune health post for subjects who develop malaria

Contact once a year for 5 years to determine continued residency in Thmar Da commune

P. vivax collection study:

* Medical history and physical examination
* Hemoglobin level measurement
* Blood draw
* Treatment with chloroquine
* Blood draw 3 to 5 weeks after treatment in some patients 18 years of age or older

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Plasmodium Resistance in A. Gambiae

NCT00466557

Malaria Plasmodium Falciparum Malaria

COMPLETED

Innate and Acquired Resistance to Plasmodium Falciparum Malaria in Mali

NCT00669084

Malaria

COMPLETED

Examination of Protective Factors Against Severe Malaria

NCT00342043

Malaria Severe Malaria

COMPLETED

Malaria Prevalence in Children

NCT00322816

Plasmodium Falciparum Malaria

COMPLETED

Malaria and the Safety of Iron Supplements and Iron Fortification

NCT01156896

Iron Deficiency

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cohort study. Hemoglobin (Hb) and red blood cell (RBC) polymorphisms that give rise to HbE, alpha-thalassemia, G6PD-deficiency, and ABO blood groups occur at high frequency along the Thailand-Cambodia border, where Plasmodium vivax and P. falciparum have been and continue to be transmitted. To determine whether these Hb/RBC polymorphisms have been naturally selected because they confer protection against malaria and malaria-associated anemia, we will conduct a cohort study of ethnic Khmer in Cambodia. Approximately 1000 individuals of all ages will be genotyped for the four polymorphisms listed above and then followed for 5 years to determine the mean incidence rates for both P. vivax and P. falciparum malaria, stratified by genotype. Incidence rate ratios (IRRs) will be calculated for each polymorphism relative to the wildtype genotype. Differences between Hb levels during acute episodes of malaria and Hb levels at baseline will also be calculated to determine if Hb/RBC polymorphisms influence the degree of malaria-associated anemia.

P. vivax collection study. Unlike P. falciparum, P. vivax cannot be efficiently cultivated in vitro. Improved cultivation methods are needed to make progress on nearly all aspects of P. vivax malariology, including pathogenesis, naturally-acquired immunity, vaccination, and antimalarial drug resistance. We plan to improve both short- and long-term cultivation methods in order to test various hypotheses of P. vivax pathogenesis and protection. Using freshly obtained parasite isolates from individuals with P. vivax malaria, we will test whether Hb/RBC polymorphisms influence potentially pathogenic properties of P. vivax parasites, such as their ability to bind non-infected RBCs and other host cells. It is believed that P. vivax selectively invades reticutocytes. This tropism has frustrated attempts at long-term cultivation of this parasite, which requires a constant source of reticulocyte-rich blood not easily obtained even in developed countries. The host reticulocyte receptor that mediates the highly selective tropism of P. vivax has not been identified. Fresh P. vivax parasites will also be used in in vitro experiments to identify the putative receptor that defines reticulocyte tropism. Any P. vivax ligand that bound selectively to a reticulocyte receptor will then be discovered and worked up as a promising vaccine candidate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Resident of Kandal, Ekapheap, and Sangkumthmey villages (Thmar Da commune), and no plans to leave the Thmar Da commune for the next 5 years.

Willingness to participate in the study as evidenced by informed consent of subjects or his/her parent or guardian, and willingness to come to commune health posts if he/she develops fever or other symptoms of malaria.

Individuals of all ages will be enrolled.

P. vivax malaria (mono-infection).

Willingness to participate in the study as evidenced by informed consent of subjects or his/her parent or guardian.

Age greater than or equal to 2.

Hematocrit greater than or equal to 25%.

Healthy male or female adults greater than or equal to 18 years old or healthy pregnant female adults greater than or equal to 18 years old.

Willingness to participate in the study as evidenced by informed consent.

Healthy male or non- pregnant female adults greater than or equal to 18 years old.

Previous enrollment on the P. vivax collection study.

Willingness to participate in the study as evidenced by written informed consent.

Exclusion Criteria

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric disease).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric disease).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

Pregnancy.

Prior use of antimalarials during the past 2 months.

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric disease).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

For the follow-up blood draw (250 mL), symptomatic parasitemia with any species of Plasmodium.

For the follow-up blood draw (250 mL), hemoglobin level \<9 g/dL.

For the follow-up blood draw (250 mL), weight \<45 kg.

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric illness).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes